IL6 and breast cancer: The possible explanation could be that more aggressive tumors may trigger an extended inflammatory reaction during their progression, with increased levels of circulating cytokines, such as interleukin-6, CRP, and N/L ratio.23–26 These suggested that RDW may be a potential biomarker of cancer growth and metastatic activity in breast cancer.